Respiratory JC014: Fever And Purulent Sputum: Influenza, Pneumonia: Common Organisms And Anti-microbial Agents For Pneumonia Flashcards

1
Q

***Lower respiratory tract infections

A
  1. Acute bronchitis
  2. Acute exacerbation of Chronic bronchitis
  3. Bronchiectasis
  4. Pneumonia
  5. Lung abscess
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Case:
- 35 male
- chronic smoker
- good past health
- high fever 3 days
- URTI symptoms (sore throat, running nose)
- increasing cough + greenish sputum
- progressive SOB
- right side pleuritic chest pain
- high swinging fever with chills + rigors
- oral antibiotics + paracetamol but worsening

A

P/E:
- respiratory distress
- alert
- dullness
- **bronchial breath sound
- **
coarse inspiratory crackles over right lower chest
- BP 90/50 (borderline low)
- SpO2 92% on room air (RA) (low)

CXR:
- Right lower lobe consolidation

Clinical diagnosis:
- Community-acquired pneumonia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pneumonia

A

Definition:
- Inflammation of Lung ***parenchyma ∵ infective agents (Bacteria, Virus, Fungi)
- vs Pneumonitis (non-infectious cause of inflammation)

Classifications:
1. Anatomical (can be due to different agents)
- **Lobar
- Multi-lobar
- **
Bronchopneumonia

  1. Etiological
    - Bacterial
    - Viral
    - Fungal (rare)
  2. Clinical
    - CAP
    - HAP
    - VAP (ventilator)
    - Aspiration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Epidemiology of Pneumonia

A
  • 2nd leading cause of death since 2012
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Causative pathogens of Pneumonia

A

Depends on:
- Clinical settings
- Host factors

  1. Bacteria
  2. Viruses
  3. Fungi
  4. Mycobacterium TB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

***Causative Bacteria in Pneumonia

A

Gram +ve (***記: SHS):
- Streptococcus pneumoniae (CAP ++, HAP +) (Pneumococcus)
- Haemophilus influenzae (CAP +, HAP +)
- MRSA (HAP ++)

Gram -ve (***記: PK):
- Klebsiella pneumoniae, Pseudomonas aeruginosa (HAP ++)

Atypical (***記: MCL):
- Mycoplasma pneumoniae (CAP +, Aspiration +)
- Legionella pneumophila (CAP +, Aspiration +)
- Chlamydophila pneumoniae (CAP +, Aspiration +)

Anaerobes:
- Bacteroides spp. (GI / Oral flora) (Aspiration ++)

(Bronchiectasis:
- Haemophilus influenzae
- Pseudomonas aeruginosa

COPD exacerbation:
- Streptococcus pneumoniae
- Haemophilus influenzae
- Moraxella catarrhalis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Community-acquired pneumonia (CAP)

A

Symptoms:
- Cough, Sputum, Haemoptysis, **Dyspnea, **Pleuritic chest pain (indicate Pleural involvement / inflammation)
- Fever, Chills, Rigor
- Confusion, Constitutional / systemic symptoms

Signs:
- Chest: **Dullness, **Bronchial breath sound, **Coarse crackles, **↑ Vocal resonance
- Vital (assess severity): BP, SpO2, mental state

History:
- TOCC

Atypical pneumonia:
- M. pneumoniae, C. pneumoniae, L. pneumophila
- Syndrome of **pneumonitis, fever
- **
Normal WBC (esp. Neutrophil)
- Without identifiable bacterial pathogens from respiratory samples
- Prominent systemic complaints

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Clinical approach to CAP

A
  1. Establish diagnosis
  2. Identify causative pathogens
  3. Assess clinical severity
  4. Empirical anti-infective / antibiotic treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

***1. Diagnosis of CAP

A
  1. Clinical diagnosis
    - Compatible respiratory S/S
  2. Radiographic evidence
    - **Consolidations in Lobar pneumonia
    - **
    Patchy infiltrates in Bronchopneumonia
  3. Further investigations:
    - **CBC (total WBC, D/C) —> identify likely organisms
    - **
    Electrolytes —> HypoNa in SIADH
    - LFT, RFT —> adjust antibiotic dose
    - ***ABG —> assess gas exchange
  4. Identify causative organism (Retrospective)
    - **Sputum + Blood cultures
    - **
    Nasopharyngeal aspirate (if suspect influenza / atypical pneumonia) —> Viral studies, RT-PCR
    - ***Urine Ag test (for Legionella, Pneumococcus) (SpC Medicine: Specific, Sensitive, Rapid (hours), Cheap, +ve from day 3 - several weeks, Not affected by antibiotics)
    - Atypical pneumonia serology —> retrospective diagnosis for atypical pneumonia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  1. Initial management of CAP
A

Identifying causative agents
- Microbiological diagnosis: ***Retrospective
- still important to know about Antibiotic resistance (help refinement of antibiotic choice)

Initial management is based on Clinical setting + Hosts factors
- Co-morbidities
- Immunocompromised?
- Previous antibiotic use (prone to develop antibiotic resistance)
- Need to cover Streptococcus pneumoniae in **ALL cases of CAP
- Need to cover Legionella pneumophila in **
SEVERE cases of CAP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  1. Assess clinical severity of CAP
A

Help to decide an appropriate clinical setting for management
- Outpatient
- General medical ward
- ICU

Poor prognostic factors:
- Old age
- Hypoxaemia (PaO2 <8 kPa i.e. already respiratory failure)
- High (>11) / Low (<4) total WBC
- High urea (>8)
- Multilobar involvement
- Bacteraemia (positive blood culture)

***CURB-65 (>2 factors present —> hospital admission)
- Confusion
- Urea >7
- RR >30
- BP low (SBP <90 / DBP <60)
- >65 yo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Empirical antibiotics for CAP

A
  • Appropriate antibiotics
  • Timely (within 6-8 hours)

Choice depends on Clinical settings + Risk factors for multi-resistant pathogens
- Need to cover Streptococcus pneumoniae in **ALL cases of CAP
- Need to cover Legionella pneumophila in **
SEVERE cases of CAP (Macrolide (SpC Medicine))

Treatment:
Penicillin with β-lactamase inhibitor (+/- Macrolide / Tetracycline)
- **Augmentin +/- **Clarithromycin / Azithromycin / Doxycycline
- 7-10 days

Risk factors for multi-resistant pathogens:
- Recent / Frequent antibiotic use
- Recent / Frequent hospitalisation
- Nursing home residents
- Immunosuppressive disease / therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

General supportive therapy for Pneumonia

A
  1. ***O2 / Mechanical ventilation for respiratory failure
  2. Chest physiotherapy
  3. ***Fluid rehydration (prevent high urea)
  4. Treat underlying COPD with bronchodilators
  5. ***Control cardiac arrhythmia (e.g. AF)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hospital-acquired pneumonia (HAP)

A

Pneumonia **>48 hours after hospitalisation
- related to aspiration of **
oropharyngeal secretions colonised by hospital-acquired organisms
- more resistant bacteria (
MRSA) + Gram -ve bacilli (記: ***PK: P. aeruginosa, K. pneumoniae)

Predisposing factors:
- General debility
- Old age
- Smoking
- COPD
- **Aspiration
- **
Post-general anaesthesia (GA)
- H2 blockers / Antacids
- **NG tube
- **
Mechanical ventilation (Ventilator-associated pneumonia (VAP))

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Empirical antibiotics for HAP

A

Cover:
1. Streptococcus pneumoniae
2. Resistant Gram +ve (may include MRSA if appropriate)
3. Gram -ve (
P. aeruginosa, ***K. pneumoniae, Extended spectrum β-lactamase (ESBL) producing organisms)
4. Anaerobes (∵ aspiration)

Treatment:
Extended spectrum Penicillin / 3rd gen Cephalosporin / Carbapenem
- **Piperacillin-Tazobactam
- **
Meropenem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Aspiration pneumonia (+ SpC Medicine)

A

Predisposing factors:
- **Altered consciousness (e.g. Syncope / CVA, Epilepsy)
- **
Alcoholism
- Vomiting
- Dysphagia, Esophageal diseases (e.g. Ca esophagus, esophageal stricture)
- **
Neurological disorders (
Bulbar palsy, Bulbar: Brainstem - Midbrain + Cerebellum, MG, Dermatomyositis, Scleroderma, Motor neuron disease)
- **
NG tube
- Severe dental / URTI
- Terminal illness
- Drowning
(- Musculoskeletal problem e.g. Scoliosis
- Tracheo-esophageal fistula)

Causative agents:
- ***Anaerobes (oral flora)

Clinical features:
Usually affecting **dependent parts of lungs
- **
Lower lobes (esp. **Right: vertical, short, wide)
- Posterior segments of upper lobes (in those mostly supine)
- Component of **
chemical pneumonitis as well —> delayed CXR resolution, prone to lung abscess

Investigations:
- ***Videofluoroscopic swallowing study (VFSS)
—> assess integrity of swallowing

17
Q

Management of Aspiration pneumonia

A
  1. Antibiotics
    - cover Oropharyngeal flora esp. **Anaerobes (e.g. Metronidazole)
    - **
    Penicillins (e.g. Augmentin)
  2. Treat underlying conditions
  3. Prevention of further aspiration
    - non-oral feeding (e.g. via Percutaneous endoscopic gastrostomy (***PEG tube) in bulbar dysfunction patients)
18
Q

***Complications of Pneumonia

A
  1. ***Respiratory failure
    - O2 therapy
    - Ventilatory support
  2. ***Septicaemia with Multi-organ failure (Septic shock)
  3. **Lung abscess
    - Air-fluid level, Cavity on CXR
    - could be **
    polymicrobial
    - need prolonged antibiotics (4-6 weeks)
    - no need percutaneous drainage in most cases (∵ drain naturally via airway)
  4. ***Parapneumonic effusion
    - ∵ pleural inflammation without infection of pleural cavity
  5. Empyema thoracis
    - infection of pleural cavity (pathogen invaded into pleura)
    - pus in pleural cavity
    —> gross appearance of pleural fluid
    —> Gram’s stain
    —> culture
    - need prolonged antibiotics (4-6 weeks)
    - ***Pleural drainage needed (e.g. Intercostal tube) (∵ no natural drainage)
  6. SIADH
    - HypoNa
  7. Acute MI
  8. ***Cardiac arrhythmia (AF)
19
Q

Recurrent pneumonia

A

Causes:
1. **Diffuse bronchopulmonary diseases (e.g. Bronchiectasis: destroyed airway, chronic colonisation of airways)
2. **
Recurrent aspiration
3. ***Immunocompromised (e.g. HIV, malignancy)
4. Bronchial obstruction (∵ retained secretions e.g. by tumour, foreign body)

Investigations:
1. **CT thorax
2. **
Bronchoscopy (visualise airway + obtain samples) —> e.g. for TB
3. Sputum —> AFB + Cytology (malignancy)
4. Blood —> look for immunodeficiency

20
Q

Influenza

A

Influenza virus:
- Influenza A + B
- Immunogenic surface Ag
—> Haemagglutinin (H)
—> Neuraminidase (N)

Antigenic shift: ***Major changes in Ag (e.g. H3N2 —> H1N1)
- highly pathogenic
- human do not have specific natural immunity
- worldwide pandemics

Antigenic drift: ***Minor changes in Ag
- occur continuously yearly

21
Q

Seasonal influenza

A

2 peaks
- Jan —> Mar
- Jul —> Aug

22
Q

Clinical features of Influenza

A
  1. **URT symptoms
    - **
    running nose
    - ***sore throat
    - cough + sputum
  2. Fever, Myalgia, Arthralgia
  3. LRT / Systemic involvement (occasional)
23
Q

Diagnosis of Influenza

A
  1. Rapid Ag test on nasopharyngeal aspirate (NPA) / swab
    - distinguish A / B
  2. ***RT-PCR
    - information of virus strain
  3. Viral cultures
  4. Serology
    - retrospective epidemiological diagnosis
24
Q

Management of Influenza

A
  1. Personal hygiene
  2. Symptomatic treatment (∵ self-limiting)
  3. Specific antivirals
    - Amantadine / Rimantadine
    - Neuraminidase inhibitors
25
Amantadine / Rimantadine
- Interfere with viral ***uncoating inside cells - Effective ONLY against ***influenza A - Not useful in treating Avian flu - Severe toxic effects (mainly neurological) - Rapid emergence of drug ***resistance
26
Neuraminidase inhibitors
Interfere with release of progeny influenza virus from infected host cells —> Stop spread of infection in respiratory tract - Effective against influenza ***A+B - Active when give asap (within ***48 hours) - Oseltamivir (Tamiflu: Oral), Zanamivir (Relenza: Inhaled)
27
***Bronchiectasis
- Pathological dilatation of bronchi - Chronic destruction of bronchi (***colonised by bacteria) - Generalised / Localised Causes: 1. ***Mostly idiopathic (need to look out for secondary causes before concluding idiopathic) 2. Secondary causes - ***Post-infection - ***Post-TB - ***Immunodeficiency - ***Autoimmune (e.g. RA) - Aspiration - Primary ciliary dyskinesia - Cystic fibrosis Symptoms: 1. ***Chronic sputum production + cough 2. Episodes of infective ***exacerbations (∵ retention of secretions in mucosal surface since cannot be cleared —> overgrowth of bacteria) 3. ***Haemoptysis: usually infective 4. Dyspnea, Chest pain, Weight loss, Fatigue Signs: 1. Cachexic 2. ***Clubbing 3. ***Coarse crackles, ***↓ Breath sound, ***Dull 4. Associated COPD 5. ***Respiratory failure 6. Progressive lung damage 7. ***Lung abscesses 8. ***Empyema 9. Brain abscess 10. Other complications
28
***Investigations of Bronchiectasis
1. CXR - may be normal / ***tramline shadows (bronchi do not taper, parallel), ***signet ring sign (prominently dilated airway compared to its accompanying pulmonary vessels) 2. ***HRCT thorax (Gold standard) 3. ***Immunoglobulins - look for secondary cause (e.g. deficiency can cause repeated infections) 4. ***Auto-Ab - look for secondary cause (e.g. RA) 5. Sputum culture, ***AFB 6. Barium studies / 24 hour esophageal pH monitoring - repeated reflux / aspiration 7. Ciliary / Sperm analysis - ***Primary ciliary dyskinesia (congenital: impaired ciliary function) 8. Neutrophil functions (rare) 9. Sweat test (measure amount of Cl in sweat: very high Cl —> cystic fibrosis) - ***Cystic fibrosis
29
***Treatment of Bronchiectasis
Acute exacerbations: - Haemophilus influenzae - Staphylococcus aureus - ***Pseudomonas aeruginosa (if long-standing) (poor prognosis) 1. Anti-pseudomonal antiobiotics - ***Extended spectrum penicillins (e.g. ***Piperacillin-Tazobactam) - ***3rd gen Cephalosporin (e.g. ***Ceftazidime) - ***Carbapenems (e.g. ***Meropenem) - Aminoglycoside (e.g. Amikacin) (Inhaled form: if colonisation by Pseudomonas + frequent exacerbation, SE: Bronchospasm, Ototoxicity, Vestibular toxicity, Nephrotoxicity (SpC Medicine)) - Fluoroquinolone (e.g. Levofloxacin) —> Only Orally available (others IV) 2. ***ICS +/- LABA - in overlapped airflow obstructive disease (- not routine use in bronchiectasis only (SpC Medicine) (支氣管擴張不用再擴張氣管)) 3. Long-term macrolides - ***Immunomodulating rather than antibiotic effect - Azithromycin, Erythromycin - watch out for ***prolonged QTc, ***sensorineural hearing impairment (- for recurrent exacerbation (SpC Medicine)) 4. ***Postural drainage - use gravity to drain retained mucus 5. Chest physiotherapy 6. Surgery - for localised bronchiectasis - very limited disease 7. Lung transplantation (SpC Medicine) 8. ***Vaccination - Streptococcus pneumoniae - Influenza 9. Pulmonary rehabilitation
30
Severity grading system for Bronchiectasis (SpC Medicine)
1. ***Bronchiectasis severity index Parameters - Age - BMI - %FEV1 Predicted - Previous hospital admission (Has the patient been hospitalised with a severe exacerbation in the past 2 years?) - Number of exacerbations in previous year - MMRC Breathlessness Score - Pseudomonas colonisation (chronic colonisation is defined by the isolation of Pseudomonas aeriginosa in sputum culture on >=2 occasions, >=3 months apart in a 1 year period) - Colonisation with other organisms (chronic colonisation is defined by the isolation of potentially pathogenic bacteria in sputum culture on 2 or more occasions, at least 3 months apart in a 1 year period) - Radiological severity Score: - 0-4 points: Mild bronchiectasis - 5-8 points: Moderate bronchiectasis - >=9 points: Severe bronchiectasis 2. ***FACED score - F: FEV1 (>=50% = 0 points, <50% = 2 points) - A: Age (<70 years = 0 points, >=70 years = 2 points) - C: Chronic colonisation (no Pseudomonas = 0 points, presence of Pseudomonas = 1 point) - E: Extension (1-2 lobes affected = 0 points, >2 lobes affected= 1 point) - D: Dyspnea (modified Medical Research Council scale (mMRC)) (0-2 = 0 points, 3-4 = 1 point) Score: - 0-2 points: Mild bronchiectasis - 3-4 points: Moderate bronchiectasis - 5-7 points: Severe bronchiectasis
31
Silouette sign on CXR (SpC Medicine)
When 2 structures of similar density are side by side, their borders become undefinable on a plain XR - When a lung lobe is collapsed / consolidated —> density is similar to heart —> if on RML / LUL (where the heart situated in between) —> cannot see border of consolidation vs —> if on RLL / LLL (behind the heart) —> can see border of consolidation clearly Philip Li: - Cannot see heart border: Middle lobe - Cannot see diaphragm: Upper lobe
32
Lung abscess (SpC Medicine)
Suppurative lung lesion with cavity on CXR Cavitating organism causing lung abscess: 1. TB 2. Klebsiella 3. Staphylococci aureus Solitary lung abscess: 1. ***Inadequately treated pneumonia (esp. Staphylococcus aureus, Klebsiella) 2. ***Bronchiectasis-associated 3. Aspiration 4. FB / Tumour obstruction 5. Amoebic, from liver amoebic abscess (in RLL) Multiple lung abscesses: 1. ***Septicaemia (via RV + RA) 2. ***IV catheter (esp. prolonged use for chemotherapy (Hickmann’s catheter) / vascular access for HD) 3. ***IV drug abuse (severe phlebitis) 4. R-sided endocarditis (echo) P/E: 1. Vital signs 2. Respiratory exam 3. Heart complications - Severe phlebitis and evidence of IV drug abuse - Splinter haemorrhage - Murmurs 4. Brain abscess - Conscious level - Focal motor signs - Fundi: haemorrhage / papilloedema (increased ICP) 5. Urinalysis: RBC suggestive of microscopic haematuria Investigations: 1. CXR: Suppurative lung lesion with cavity 2. CBP + D/C 3. LRFT 4. Blood culture 5. Sputum for Gram stain, C/S 6. Sputum for ova and parasite - whenever a parasitic cause for lung abscess is suspected 7. FOB 8. Echocardiogram (despite no murmur, vegetation may still be present in heart) 9. Full septic workup: HBV, HCV, HIV, MRI brain as indicated Treatment: 1. High-dose IV empirical antibiotics - Depending on scenarios and cultures, e.g. aspiration, bronchiectatic / parasitic abscess - Prolonged duration (4-6 weeks) - No need of percutaneous drainage in most cases (because natural drainage through airway)
33
IV drug abuse-associated disease
1. Addiction 2. Direct abuse drug toxicity (e.g. morphine overdose) 3. Phlebitis + thrombosis 4. Multiple lung abscesses 5. Other organ abscesses - Brain abscess —> MRI brain - Liver abscess (pathogens not completely filtered off in lung but carried to systemic circulation) 6. R-sided infective endocarditis (S. auerus) 7. HBV / HCV infections 8. HIV infections 9. Tetanus
34
Pneumocystis pneumonia (PCP)
- Pneumocystis jirovecii (previously P. carinii) - AIDS-defining illness —> Lymphopenia —> ***Reversed CD4:CD8 ratio (normal 1-4 (web)) —> ***CD4 <200 very likely cause opportunistic infections CXR: - ***Bilateral Diffuse ground glass opacity (Pathognomonic) (DDx: Viral infection e.g. CMV (SpC Revision)) - Lymphopenia Diagnosis: - ***Induced sputum / BAL fluid: cysts of P. jirovecii in lung tissue, stained with ***Silver stain - ***NPA for PCR - Cannot be cultured - Lung biopsy not done since too invasive Treatment: 1. ***21 days ***Co-trimoxazole (Septrin) - PO/IV (= IV Pentamidine) - CI in G6PD: must check status 2. ***Adjunctive steroid for severe PCP with PaO2 <9kP - Cytokine storm may happen after killing of microbes with cotrimoxazole —> give adjunctive steroid to damp down severe cytokine storm / inflammatory response Prophylaxis: 1. Primary: CD4 <200 2. Secondary: with history of PCP - Co-trimoxazole in prophylactic dose (unless HAART renders CD4 >200 >3m)
35
Primary Ciliary Dyskinesia (KWH Paed Teaching)
Inheritance: - Autosomal recessive mainly Clinical features: 1. Pulmonary - Chronic productive cough - Recurrent pneumonia - Recurrent rhinosinusitis 2. Eustachian tube - Otitis media 3. CNS - Headache, fatigue 4. Fertility - Immotile sperm - Ectopic pregnancy Associated symptoms: - Situs inversus - Kartagener syndrome: Triad of Situs inversus, Chronic sinusitis, Bronchiectasis - Transposition of great vessels, other cardiac abnormalities - Pyloric stenosis - Epispadias Diagnosis: - ***PICADAR score (Prerequisite question: Does patient have daily wet cough that started in early childhood?) - ***Ciliary brush - ***Nasal NO (Very low / absent) Management: 1. ***Antibiotic for infections 2. Airway clearance therapy - ***Oscillating PEP device, Chest physiotherapy - ***Nasal washing - Hypertonic saline 3. Vitamin D (for chronic lung disease) 4. Vaccination
36
DDx of Micronodular shadowing on CXR (SpC Revision)
1. Lymphangitis carcinomatosis 2. Miliary TB 3. Silicosis 4. Sarcoidosis 5. Pulmonary haemosiderosis
37
DDx of Diffuse ground glass appearance on CXR (SpC Revision)
Ground glass: - Increased attenuation of the lung with preserved bronchial and vascular markings (web) For patients on immunosuppressants: 1. Pneumocystis jirovecii pneumonia 2. Viral infection (e.g. CMV) Self notes: 1. Atypical pneumonia (e.g. Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) 2. Interstitial lung disease (Pulmonary fibrosis) 3. Pulmonary edema
38
Diagnosis of TB and PCP (SpC PP)
TB: 1. ZN stain 2. AFB smear 3. PCR 4. Culture PCP: 1. Silver stain 2. Cysts of PCP 3. PCR